Neurogene Inc. (NASDAQ: NGNE) is a Healthcare company (Biotechnology) with a market capitalization of $365M. The Maz Rating grades it against the other companies in its sector.
Neurogene Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $23.10, Neurogene Inc. trades at 1.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -44.4%, return on invested capital of -35.8% and a free cash flow yield of -26.5%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 19.97. Over the past 52 weeks the share price ranged from $15.93 to $43.66, with a beta of 2.09.
Neurogene Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.